Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Spirogen Ltd.
The antibody-drug conjugate yields a 48% overall and 24% complete response rate in a pivotal Phase II DLBCL study. The Swiss biotech hopes to compete with Polivy and is studying combo therapy with Imbruvica.
Swiss oncology company ADC Therapeutics, which has just added another $200m to its coffers, is developing a new class of antibody-drug conjugates that may be less visible to DNA repair mechanisms and therefore less susceptible to the development of resistance than other anticancers.
Regeneron stayed busy during the past two weeks, collaborating and making an equity commitment to CRISPR gene-editing biotech Intellia and signing an immuno-oncology deal with MedImmune. Allergan bounced off the termination of its merger with Pfizer by partnering with Heptares in neurological disease.
Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.